Search, analyze & compare
My selected companies
Adjust valuation method
![]()
Detail of Ginkgo Bioworks Holdings, Inc.
CEO
Dr. Jason Kelly
Employees
641
Industry
Biotechnology
Sector
Healthcare
Market cap
$13B
Company details
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OI
OIE
PI
TAX
NI
Revenue (Rev)
$184.34M
Cost of goods (CoG)
-$36.46M
Gross profit (GP)
$147.88M
Operating expense (OE)
-$852.20M
Research and development (R&D)
-$544.38M
General and administrative (G&A)
-$307.82M
Operating income (OI)
-$704.32M
Other income expense (OIE)
-$243.61M
Pretax income (PI)
-$897.68M
Tax (TAX)
-$1,000.00
Net income (NI)
-$897.68M
Stock vs Industry average
-
Industry average
Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$0.44
Margin profit
78.52%
52 week low
$0.2101
52 week high
$9.36
50-day simple moving average
$5.78
200-day simple moving average
$5.32
Percent held by insiders
6.43%
Percent held by institutions
63.87%
Dividend yield
0.00%
